Filing Details
- Accession Number:
- 0001209191-13-042409
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-08-29 21:08:30
- Reporting Period:
- 2013-08-28
- Filing Date:
- 2013-08-29
- Accepted Time:
- 2013-08-29 21:08:30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 816284 | Celgene Corp | CELG | Pharmaceutical Preparations (2834) | 222711928 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1538894 | O Thomas Daniel | C/O Celgene Corporation 86 Morris Avenue Summit NJ 07901 | See Remarks | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2013-08-28 | 25,000 | $66.59 | 40,349 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2013-08-28 | 5,389 | $62.42 | 45,738 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2013-08-28 | 1,874 | $49.61 | 47,612 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2013-08-28 | 32,263 | $137.06 | 15,349 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2013-08-28 | 25,000 | $0.00 | 25,000 | $66.59 |
| Common Stock | Stock Option (right to buy) | Disposition | 2013-08-28 | 5,389 | $0.00 | 5,389 | $62.42 |
| Common Stock | Stock Option (right to buy) | Disposition | 2013-08-28 | 1,874 | $0.00 | 1,874 | $49.61 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2017-09-06 | No | 4 | M | Direct | |
| 0 | 2018-04-08 | No | 4 | M | Direct | |
| 0 | 2018-01-08 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,395 | Indirect | 401(k) Plan |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were pursuant to the reporting person's Rule 10b5-1 plan dated March 28, 2013 in multiple transactions at prices ranging from $136.15 to $137.57, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- The option was fully exercisable.
- The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as amended).
Billionaire Hedge Funds
